Imran B.

Imran B. has extensive experience in the biopharmaceutical industry. Imran began their career in 2011 as a Biotechnology Associate at Cowen & Co., where they provided investment banking services, equity and credit research, sales and trading, prime brokerage, global clearing, commission management services and actively managed alternative investment products. In 2013, they joined OrbiMed Advisors as a Vice President and Private Equity Senior Associate. Here, they worked with a leading healthcare investment firm with $14 billion in assets under management. In 2018, Imran became the Chief Business Officer of Cydan, a venture-backed orphan drug accelerator. In 2019, they co-founded Tiburio Therapeutics, a company dedicated to advancing novel treatments for serious neuroendocrine disorders. In 2020, they took on the role of Manager at Biotech Consulting and Co-Founder at Arvada Therapeutics. Currently, Imran is the Chief Business Officer of Sudo Biosciences and Co-Founder and Chief Business Officer of Calance Therapeutics.

Imran B. has a Ph.D. in Molecular Biology from Yale University and a Bachelor's degree in Biology from Carleton College.